Revenue
2018
2019
2020
2021
2022
2023
2024
2025
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $40.9M | $32.6M | $19.2M | $15.6M | $13.9M | $7.6M | $3.8M | $2.4M | $1.6M | $1.1M |
| Gross profit | $26.9M | $23.2M | $13.2M | $10.3M | $10.3M | $5.0M | $2.4M | $1.7M | $1.1M | $821,113 |
| Research & development | $6.9M | $4.8M | $2.6M | $2.5M | $2.6M | $1.7M | $1.7M | $1.8M | $1.8M | $1.1M |
| Operating expenses | $41.3M | $29.4M | $21.4M | $20.9M | $20.6M | $15.5M | $13.2M | $12.2M | $7.6M | $4.1M |
| Operating income | −$14.4M | −$6.2M | −$8.2M | −$10.7M | −$10.3M | −$10.5M | −$10.8M | −$10.5M | −$6.5M | −$3.3M |
| Net income | −$15.6M | −$6.2M | −$8.1M | −$10.7M | −$10.4M | −$11.6M | −$10.7M | −$10.3M | −$12.1M | −$3.6M |
| Basic EPSper diluted share | -$0.37 | -$0.16 | -$0.28 | -$1.52 | -$1.89 | -$3.67 | -$20.79 | -$25.18 | -$2.93 | -$4.13 |
| Diluted EPSper diluted share | -$0.37 | -$0.16 | -$0.28 | -$1.52 | -$1.89 | -$3.67 | -$20.79 | -$25.18 | -$2.93 | -$4.13 |
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 5, 2026Form 4 | KIRK THOMAS FDirector | BuyCommon Stock | 40.0K | $1.27 | $50.8K | 693.9K |
| May 28, 2026Form 4 | KIRK THOMAS FDirector | BuyCommon Stock | 25.0K | $0.99 | $24.8K | 653.9K |
| May 28, 2026Form 4 | Kovelman HarryChief Medical Officer | SellCommon Stock | 11.5K | $1.02 | $11.8K | 108.6K |
| May 27, 2026Form 4 | Kovelman HarryChief Medical Officer | SellCommon Stock | 20.5K | $1.00 | $20.5K | 120.2K |
| May 18, 2026Form 4 | KIRK THOMAS FDirector | BuyCommon Stock | 43.4K | $0.91 | $39.5K | 628.9K |